AZN

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -1.49
Percentage change -2.20	%

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM PVAL FVD TQQQ DIHP DFIC PPH AVDE QYLD

Scroll to Statements

Index	NDX	P/E	26.61	EPS (ttm)	2.49	Insider Own	0.05%	Shs Outstand	3.10B	Perf Week	-5.48%
Market Cap	205.40B	Forward P/E	13.03	EPS next Y	5.08	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-2.62%
Income	7.77B	PEG	2.38	EPS next Q	1.10	Inst Own	16.58%	Short Float	0.16%	Perf Quarter	-11.02%
Sales	54.98B	P/S	3.74	EPS this Y	9.64%	Inst Trans	-1.61%	Short Ratio	0.79	Perf Half Y	2.70%
Book/sh	13.23	P/B	5.00	EPS next Y	12.91%	ROA	7.45%	Short Interest	4.82M	Perf Year	-14.19%
Cash/sh	1.74	P/C	38.07	EPS next 5Y	11.16%	ROE	19.81%	52W Range	61.24 - 87.68	Perf YTD	1.08%
Dividend Est.	1.61 (2.43%)	P/FCF	17.91	EPS past 5Y	34.63%	ROI	11.28%	52W High	-24.46%	Beta	0.37
Dividend TTM	1.55 (2.34%)	Quick Ratio	0.70	Sales past 5Y	17.77%	Gross Margin	72.58%	52W Low	8.15%	ATR (14)	1.83
Dividend Ex-Date	Feb 21, 2025	Current Ratio	0.90	EPS Y/Y TTM	22.70%	Oper. Margin	20.63%	RSI (14)	38.78	Volatility	2.41% 2.00%
Employees	94300	Debt/Eq	0.77	Sales Y/Y TTM	15.48%	Profit Margin	14.14%	Recom	1.34	Target Price	92.06
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	33.73%	Payout	66.98%	Rel Volume	0.92	Prev Close	67.72
Sales Surprise	-1.60%	EPS Surprise	11.52%	Sales Q/Q	7.17%	Earnings	Apr 29 BMO	Avg Volume	6.11M	Price	66.23
SMA20	-4.26%	SMA50	-7.25%	SMA200	-9.49%	Trades		Volume	5,630,582	Change	-2.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

May-13-25 04:59PM	Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? (Insider Monkey)
09:56AM	Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:00AM	AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 (Business Wire)
05:10AM	MHRA approves AstraZenecas Trixeo Aerosphere inhaler for COPD (Pharmaceutical Technology)
04:54PM	Loading…
May-12-25 04:54PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
07:38AM	Trumps Vow to Cut US Drug Prices Drags Pharma Stocks Lower (Bloomberg)
07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
07:15AM	AstraZenecas Imfinzi combo shows DFS improvement in bladder cancer trial (Clinical Trials Arena)
04:28AM	Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg)
May-09-25 09:55AM	How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89% (Zacks)
08:51AM	Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update (Zacks)
07:00AM	IMFINZI (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial (Business Wire)
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks)
07:45AM	Tempus AI Stock: Time to Double Down or Cut and Run? (MarketBeat)
05:37AM	Loading…
05:37AM	AstraZeneca, Daiichis Enhertu shows pCR rate improvement in breast cancer trial (Clinical Trials Arena)
05:37AM	AstraZeneca and Daiichis Enhertu shows pCR rate improvement in breast cancer trial (Clinical Trials Arena)
May-07-25 11:18PM	Hartford International Equity Fund Q1 2025 Commentary (Seeking Alpha)
05:46PM	Hartford International Opportunities Fund Q1 2025 Commentary (Seeking Alpha)
02:54PM	AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer (Seeking Alpha)
10:14AM	Q1 2025 Arcus Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
07:04AM	Expediting parallel drug approval pathways is challenging, but rewarding (Pharmaceutical Technology)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 (Business Wire)
05:13AM	EC approves AstraZenecas Calquence combo to treat MCL (Pharmaceutical Technology)
03:22AM	Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
May-06-25 03:52PM	AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing (Fox Business)
11:40AM	AZN or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
May-05-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-02-25 01:00PM	Here's what top C-suites are saying about tariffs (Yahoo Finance Video)
10:18AM	AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma (Benzinga)
08:58AM	Loading…
08:58AM	Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. (Motley Fool)
07:50AM	Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth (Zacks)
07:36AM	AstraZenecas triple-combo triumphs in two Phase III asthma trials (Clinical Trials Arena)
07:02AM	Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma (BioPharma Dive)
07:00AM	BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma (Business Wire)
May-01-25 12:06PM	'Declare victory and move on': Eli Lilly CEO on Trump tariff threat (Yahoo Finance)
11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
10:42AM	Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View (Zacks)
07:54AM	AstraZeneca quietly exits neuroscience (BioPharma Dive)
Apr-30-25 10:20PM	Templeton Foreign Fund Q1 2025 Commentary (Seeking Alpha)
12:03PM	Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC (Clinical Trials Arena)
07:06AM	AstraZenecas Truqap fails in another Phase III trial (Pharmaceutical Technology)
03:06AM	AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
Apr-29-25 04:15PM	AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss (Investor's Business Daily)
04:10PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
02:26PM	AstraZeneca CEO calls for increased European investment in pharma (Pharmaceutical Technology)
01:16PM	Pfizer CEO: 'We should not have tariffs' on pharma (Yahoo Finance)
12:05PM	AstraZeneca CEO: Trump tariffs 'not material long term' (Yahoo Finance)
11:46AM	AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha)
10:36AM	Buy our cancer drugs or jobs will go overseas, AstraZeneca warns (The Telegraph)
10:18AM	AstraZeneca's 'number 1 priority' is the US, CEO says (Yahoo Finance Video)
09:40AM	Here's Why Astrazeneca (AZN) is a Strong Value Stock (Zacks)
09:30AM	Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops (Investor's Business Daily)
09:12AM	AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs (Zacks)
07:00AM	EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire)
05:40AM	AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China (The Wall Street Journal)
05:16AM	AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors (Reuters)
05:06AM	Astrazeneca: Q1 Earnings Snapshot (Associated Press Finance)
02:00AM	AstraZeneca's Q1 2025 Financial Results (Business Wire)
Apr-28-25 07:00PM	Coca-Cola earnings, JOLTS, Consumer Confidence: What to Watch (Yahoo Finance Video)
06:57PM	AstraZeneca PLC (OSTO:AZN) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
12:23PM	SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR (PR Newswire)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
06:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
07:29AM	Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care (Pharmaceutical Business Review)
04:49AM	The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS (Zacks)
Apr-24-25 05:00PM	STAAR Surgical Announces Changes to Board of Directors (Business Wire)
03:00PM	Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? (Zacks)
02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
09:15AM	Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:59AM	Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth (Zacks)
07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
07:33AM	AstraZeneca enters $200m AI cancer pact with Tempus and Pathos (Pharmaceutical Technology)
06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-23-25 12:04PM	AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat (The Telegraph)
08:00AM	Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology (Business Wire)
05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-22-25 06:15PM	Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know (Zacks)
04:10PM	AstraZeneca rejoins leading U.S. drug lobby group after two-year absence (Reuters)
02:29PM	Regeneron to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
07:32AM	Merck Q1 Earnings Coming Up: Should You Buy the Stock Now? (Zacks)
05:50AM	Daiichi and AstraZenecas Enhertu shows PFS benefits in breast cancer trial (Clinical Trials Arena)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
01:36PM	Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? (Zacks)
08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
08:05AM	AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients (Benzinga)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer (Business Wire)
05:24AM	Enhertu combo tops standard drugs in first-line HER2 breast cancer (BioPharma Dive)
02:30AM	ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer (Business Wire)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
09:15AM	Selling America, Buying Europe - My Picks (Seeking Alpha)
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc ADR

Upgrade your FINVIZ experience